print

Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab

author
Hagström, Emil
Steg, P. Gabriel
Szarek, Michael
Bhatt, Deepak L.
Bittner, Vera A.
Danchin, Nicolas
Diaz, Rafael
Goodman, Shaun G.
Harrington, Robert A.
Jukema, J. Wouter
Liberopoulos, Evangelos
Marx, Nikolaus
Viigimaa, Margus
statement of authorship
Emil Hagström, P. Gabriel Steg, Michael Szarek, Deepak L. Bhatt, Vera A. Bittner, Nicolas Danchin, Rafael Diaz, Shaun G. Goodman, Robert A. Harrington, J. Wouter Jukema, Evangelos Liberopoulos, Nikolaus Marx, [...], Margus Viigimaa
source
Circulation
publisher
journal volume number month
vol. 146, 9
year of publication
pages
p. 657 - 672
url
ISSN
0009-7322
notes
Bibliogr.: 41 ref
Open Access
Open Access
scientific publication
teaduspublikatsioon
language
inglise
subject term
keyword
acute coronary syndrome
apolipoproteins B
cholesterol, LDL
heart disease risk factors
PCSK9 inhibitors
Reserch Group
Research group on diagnostics and treatment technologies of hypertension and atherosclerosis
Hagström, E., Steg, P.G., Szarek, M., Bhatt, D.L., Bittner, V.A., Danchin, N., Diaz, R., Goodman, S.G., Harrington, R.A., Jukema, J.W., Liberopoulos, E., Marx, N., Viigimaa, M. et al. Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab // Circulation (2022) vol. 146, 9, p. 657 - 672. https://doi.org/10.1161/CIRCULATIONAHA.121.057807